[
    [
        {
            "time": "2018-09-14",
            "original_text": "CRON Goes Up In Smoke On Citron Report, Hot AFMD Is Cooling Now, REPL On Watch",
            "features": {
                "keywords": [
                    "CRON",
                    "Citron Report",
                    "AFMD",
                    "REPL"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 2,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-09-14",
            "original_text": "U.S. Stocks Snap Four-Day Win Streak on Renewed China Trade Concerns",
            "features": {
                "keywords": [
                    "U.S. Stocks",
                    "China Trade",
                    "Concerns"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "global trade",
                    "economy"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 10,
                "Time_Proximity": 10,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-09-14",
            "original_text": "Pfizer’s Quarterly Revenues and Estimates for 2018",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Quarterly Revenues",
                    "Estimates",
                    "2018"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-09-14",
            "original_text": "Pfizer’s Developments in August",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Developments",
                    "August"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Pfizer’s Developments in August",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-09-14",
            "original_text": "Pfizer (PFE) Up 3.1% Since Last Earnings Report: Can It Continue?",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Earnings",
                    "Stock Performance"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-09-14",
            "original_text": "Pfizer’s Stock Performance in August",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Stock Performance",
                    "August"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Pfizer’s Stock Performance in August",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-09-14",
            "original_text": "Scholar Rock stock tumbles 11% as Pfizer discontinues similar medication",
            "features": {
                "keywords": [
                    "Scholar Rock",
                    "Pfizer",
                    "Discontinues",
                    "Medication"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 1,
                "Importance": 8,
                "Impact": 7,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-09-14",
            "original_text": "Dow Movers: DWDP, PFE",
            "features": {
                "keywords": [
                    "Dow",
                    "Movers",
                    "DWDP",
                    "PFE"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "industrial",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-09-14",
            "original_text": "Amgen's Leukemia Drug Blincyto Gets EU Nod for Pediatric Use",
            "features": {
                "keywords": [
                    "Amgen",
                    "Blincyto",
                    "EU Nod",
                    "Pediatric Use"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-09-14",
            "original_text": "Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?",
            "features": {
                "keywords": [
                    "First Trust",
                    "Capital Strength ETF",
                    "Investing Radar"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "ETFs",
                    "finance"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-09-14",
            "original_text": "Pfizer stops developing therapy for the rare disease Duchenne muscular dystrophy",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Therapy",
                    "Duchenne Muscular Dystrophy"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "rare diseases"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-09-14",
            "original_text": "See what the IHS Markit Score report has to say about Pfizer Inc.",
            "features": {
                "keywords": [
                    "IHS Markit Score",
                    "Pfizer Inc."
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "analysis"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-09-14",
            "original_text": "Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies for the Treatment of Duchenne Muscular Dystrophy",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Domagrozumab",
                    "Clinical Studies",
                    "Duchenne Muscular Dystrophy"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "clinical trials"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies for the Treatment of Duchenne Muscular Dystrophy",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-09-14",
            "original_text": "3 High-Yield Healthcare Dividend Stocks Still Worth Buying",
            "features": {
                "keywords": [
                    "High-Yield",
                    "Healthcare",
                    "Dividend Stocks"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "dividends"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-09-14",
            "original_text": "Pfizer Terminates Two Duchenne Muscular Dystrophy Studies",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Terminates",
                    "Duchenne Muscular Dystrophy",
                    "Studies"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "rare diseases"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Pfizer Terminates Two Duchenne Muscular Dystrophy Studies",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]